PDPHF (Egetis Therapeutics AB) Cyclically Adjusted FCF per Share: $0.00 (As of Mar. 2026)


PDPHF Egetis Therapeutics AB PDPHF
24 GF Score
Price $0.64
GF Value $0.64
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Cyclically Adjusted FCF per Share?

Egetis Therapeutics AB PDPHF 24 Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2026. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Egetis Therapeutics AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.017. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Egetis Therapeutics AB was 9.60% per year. The lowest was -4.30% per year. And the median was 1.10% per year.

As of today (2026-06-24), Egetis Therapeutics AB's current stock price is $0.6353. Egetis Therapeutics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.00. Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF of today is .


Egetis Therapeutics AB  (OTCPK:PDPHF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Egetis Therapeutics AB Cyclically Adjusted FCF per Share Related Terms


Egetis Therapeutics AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Cyclically Adjusted FCF per Share Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PDPHF vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF falls into.


PDPHF
24GF Score
Egetis Therapeutics AB PDPHF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egetis Therapeutics AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.017/133.3862*133.3862
=-0.017

Current CPI (Mar. 2026) = 133.3862.

Egetis Therapeutics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.046 101.019 -0.061
201609 -0.030 101.138 -0.040
201612 -0.027 102.022 -0.035
201703 -0.025 102.022 -0.033
201706 -0.042 102.752 -0.055
201709 -0.022 103.279 -0.028
201712 -0.100 103.793 -0.129
201803 -0.034 103.962 -0.044
201806 -0.058 104.875 -0.074
201809 -0.035 105.679 -0.044
201812 -0.041 105.912 -0.052
201903 0.054 105.886 0.068
201906 -0.052 106.742 -0.065
201909 -0.062 107.214 -0.077
201912 -0.064 107.766 -0.079
202003 -0.065 106.563 -0.081
202006 -0.062 107.498 -0.077
202009 -0.048 107.635 -0.059
202012 -0.026 108.296 -0.032
202103 -0.023 108.360 -0.028
202106 -0.025 108.928 -0.031
202109 -0.020 110.338 -0.024
202112 -0.016 112.486 -0.019
202203 -0.019 114.825 -0.022
202206 -0.018 118.384 -0.020
202209 -0.018 122.296 -0.020
202212 -0.037 126.365 -0.039
202303 -0.031 127.042 -0.033
202306 -0.023 129.407 -0.024
202309 -0.034 130.224 -0.035
202312 -0.014 131.912 -0.014
202403 -0.018 132.205 -0.018
202406 -0.018 132.716 -0.018
202409 -0.021 132.304 -0.021
202412 -0.014 132.987 -0.014
202503 -0.018 132.825 -0.018
202506 -0.018 133.699 -0.018
202509 -0.014 133.482 -0.014
202512 -0.025 133.386 -0.025
202603 -0.017 133.386 -0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
Egetis Therapeutics AB (PDPHF) has a Cyclically Adjusted FCF per Share of $0.00 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Cyclically Adjusted FCF per Share too high?
Egetis Therapeutics AB's current Cyclically Adjusted FCF per Share is $0.00. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Egetis Therapeutics AB's Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.00. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Cyclically Adjusted FCF per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued. The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for PDPHF:

  • Cyclically Adjusted FCF per Share: $0.00
  • GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score

Get the complete analysis for PDPHF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.64
GF Value